Compare Cardinal Health Inc (CAH) vs Deere & Company (DE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cardinal Health Inc vs Deere & Company — how do they compare? Cardinal Health Inc trades at $228.8 (market cap $53.89B), while Deere & Company trades at $582.07 (market cap $157.75B). The key difference: Deere & Company is far larger — about 2.9× Cardinal Health Inc's market cap, and Deere & Company pays the higher dividend (1.11%). Which is the better fit depends on your goals.
| CAH | DE | |
|---|---|---|
Market Cap | $53.89B | $157.75B |
Sector | Health | Industrials |
52-Week High | $239.71 | $662.49 |
52-Week Low | $146.04 | $439.11 |
Enterprise Value | $58.87B | $212.58B |
Dividend Yield | 0.89% | 1.11% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cardinal Health (CAH) trades at $233.66, down 0.91% in the last session, with a bullish technical signal from moving averages and strong analyst support. The company has consistently beaten earnings estimates in recent quarters, with Q1 2026 EPS of $3.17 surpassing expectations. Revenue reached $222.58 billion in 2025, though net margins remain thin at 0.62%. Recent news highlights growth potential in medical supplies, with earnings results for fiscal 2026 due August 11.
The outlook for CAH is positive, driven by earnings momentum and sector tailwinds, but risks include high leverage with debt-to-asset ratio at 16.09% and competitive pressures. Analyst consensus is bullish with a $248 price target, suggesting 6% upside. Investors should weigh solid operational cash flow against negative shareholder equity and investing outflows.
Deere & Company (DE) trades at $585.64, down 0.21% on the day, with a bearish technical signal from moving averages and oscillators. The company has beaten earnings estimates for three consecutive quarters, with Q2 2026 results pending. Revenue declined to $44.67B in 2025, though net income margin remains solid at 10.33%. Recent news highlights a $20B precision agriculture initiative and regulatory agreements enhancing farmer access to repair tools.
The outlook is mixed: analyst consensus targets $676.08 (15% upside) with 41% buy ratings, but technicals and declining revenue pose near-term risks. Key opportunities include margin strength and agtech growth; risks involve cyclical farming demand and high debt levels. Investors should weigh fundamental resilience against sector headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cardinal Health Inc
Cardinal Health is a leading pharmaceutical wholesaler, engaged in the sourcing and distribution of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail-order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and McKesson, the three compose well over 90% of the U.S. pharmaceutical wholesale industry. Cardinal Health also supplies medical-surgical products and equipment to healthcare facilities in North America, Europe, and Asia.
Read more on CAH →About Deere & Company
Deere is the world's leading manufacturer of agricultural equipment, producing some of the most recognizable machines in the heavy machinery industry. The company is divided into four reportable segments: production and precision agriculture, small agriculture and turf, construction and forestry, and John Deere Capital. Its products are available through an extensive dealer network, which includes over 1,900 dealer locations in North America and approximately 3,700 locations globally. John Deere Capital provides retail financing for machinery to its customers, in addition to wholesale financing for dealers, which increases the likelihood of Deere product sales.
Read more on DE →
